Mechanism and Effect of Beta-Blockers on Pancreatic Adenocarcinoma: A Literature Review
Abstract
Pancreatic adenocarcinoma has a poor 5-year survival rate despite many advancements in pharmacotherapies. Studies have suggested the involvement of beta-adrenergic pathway in the progression of pancreatic adenocarcinoma. Animal experiments and retrospective trials have reported the use of beta-blockers as potential chemo-preventative agents. This review aims to discuss beta-adrenergic physiology as it relates to the progression of pancreatic adenocarcinoma and review outcomes on the use of beta-blockers for its treatment.
J Clin Med Res. 2020;12(12):753-757
doi: https://doi.org/10.14740/jocmr4387